Edition:
India

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

131.01USD
16 Feb 2018
Change (% chg)

$0.34 (+0.26%)
Prev Close
$130.67
Open
$130.58
Day's High
$131.25
Day's Low
$129.78
Volume
64,635
Avg. Vol
109,209
52-wk High
$143.37
52-wk Low
$92.77

Select another date:

Tue, Feb 6 2018

BRIEF-GW Pharmaceuticals Announces EMA Accepts Epidiolex Marketing Authorization Application For Review

* GW PHARMACEUTICALS ANNOUNCES THE EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS EPIDIOLEX® (CANNABIDIOL) MARKETING AUTHORIZATION APPLICATION (MAA) FOR REVIEW

BRIEF-GW Pharma Announces Acceptance Of NDA Filing For Epidiolex (Cannabidiol)

* GW PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF NDA FILING FOR EPIDIOLEX® (CANNABIDIOL) IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME AND DRAVET SYNDROME Source text for Eikon: Further company coverage:

BRIEF-GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.

* GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S.

BRIEF-GW Pharmaceuticals Announces Pricing Of Public Offering Of ADSs Raising Gross Proceeds Of $276 Million

* GW PHARMACEUTICALS PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS RAISING GROSS PROCEEDS OF $276 MILLION

BRIEF-GW Pharmaceuticals Announces Proposed Public Offering Of ADSs

* GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

Zogenix stock soars on epilepsy drug trial success

Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .

UPDATE 3-Zogenix stock soars on epilepsy drug trial success

* Analyst expects drug to become standard in Dravet treatment

Select another date: